Clinical efficacy of combination treatment for advanced-stage axial diabetic optic neuropathy
DOI:
https://doi.org/10.31288/oftalmolzh201853944Keywords:
axial diabetic optic neuropathy, advanced stage, comprehensive treatment, efficacyAbstract
Background: There is no standard of therapy for diabetic optic neuropathy (DON) which takes into consideration the type and stage of the disease.
Purpose: To assess the clinical efficacy of combined adjunct treatment with thioctic acid, a combination of vitamins В1, В6, and В12, ethyl methyl hydroxypyridine succinate, citicoline and brimonidine tartrate in the management of advanced-stage axial DON.
Materials and Methods: Forty patients (63 eyes) were followed up after being diagnosed with advanced-stage axial DON. The adjunct group was composed of 20 patients (31 eyes) who were administered two courses a year of the following treatment as a combined adjunct to hypoglycemic therapy: 1) a 600 mg intramuscular injection of thioctic acid (Berlithion), daily for 21 days, followed by switching to oral regimen, at a dose of one 300 mg tablet twice a day for 21 days, (2) a 2 ml intramuscular injection of Milgamma, once per 3 days for 21 days, followed by switching to oral regimen, one tablet thrice a day for 21 days, (3) a 100 mg intramuscular injection of ethyl methyl hydroxypyridine succinate (Armadine), twice a day for 14 days, and (4) a 500-mg intravenous bolus of citicoline (Ceraxon), twice a day for 14 days, followed by switching to oral regimen, 500 mg daily for a month. In addition, they were administered topical brimonidine tartrate 0.2%, 1-2 drops twice a day on a constant basis. The control group (20 patients; 32 eyes) received hypoglycemic therapy only. In addition to routine eye examination, retinal and optic nerve optical coherence tomography and electrophysiology were performed. Patients underwent an examination at baseline and 1.5, 6, 7.5, 12, 13.5, 24 and 25.5 months after treatment.
Results: The combined adjunct treatment was found to result in improvements in study indices in 83.9% of patients of the adjunct group, with 191% better visual acuity (p < 0.05), 235.0% lower electrically evoked phosphene thresholds (p < 0.05), 38.5% less ganglion cell complex (GCC) focal loss volume (FLV), and 36.5% less thickness of the lamina cribrosa compared to controls at 25.5 months.
Conclusion: Our combination treatment was found to be clinically efficacious in improving structural and functional characteristics of the optic nerve in patients with advanced-stage axial DON.
References
Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543 https://doi.org/10.1002/14651858.CD007543.pub2
Kotov SV, Isakova EV, Lizhdvoi VYu, et al. [Efficacy of cocarnit in diabetic neuropathy]. Zhurnal nevrologii i psikhiatrii. 2018;1:37-42. Russian https://doi.org/10.17116/jnevro20181181137-42
Gonçalves NP, Vægter CB, Pallesen LT. Peripheral Glial Cells in the Development of Diabetic Neuropathy. Front Neurol. 2018 May 2;9:268 https://doi.org/10.3389/fneur.2018.00268
Hosseini A, Abdollahi M. Diabetic neuropathy and oxidative stress: therapeutic perspectives. Oxid Med Cell Longev. 2013;2013:1-5.
https://doi.org/10.1155/2013/168039
Effect of intensive treatment of hyperglycemia on microvascular complications of type 2 diabetes in ACCORD: a randomized trial. Lancet. 2010 Aug 7; 376(9379): 419-30
Morgunov LY. [Alpha-lipoic acid drugs in the treatment of diabetic neuropathy]. Meditsinskii sovet. 2014;17:90-4. Russian
Strokov IA, Fokina AS. [Novel potential for the treatment of diabetic complications]. RMZh. 2012;20:88-91. Russian
Chukanova EI, Chukanova AS. [Alpha-lipoic acid in the treatment of diabetic polyneuropathy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018;1:103-9. Russian https://doi.org/10.17116/jnevro201811811103-109
Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of alpha-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012; 167(4):465-71 https://doi.org/10.1530/EJE-12-0555
Jayabalan B, Low LL. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J. 2016;57(2):55-9 https://doi.org/10.11622/smedj.2016027
Papanas N, Ziegler D. Efficacy of alpha-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014; 15:2721-31 https://doi.org/10.1517/14656566.2014.972935
Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes. 1996; 104(4): 311-6 https://doi.org/10.1055/s-0029-1211460
Ziegler D, Low PA, Litchy WJ, et al. Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy. The NATHAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. https://doi.org/10.2337/dc11-0503
Bezditko PA, Karliychuk MA. Clinical and OCT features of different types and stages of diabetic optic neuropathy. J Ophthalmol (Ukraine). 2018; 1:43-8. https://doi.org/10.31288/oftalmolzh201814348
Bezditko PA, Karliychuk MA. [Clinical-diagnostic criteria of different types of nerve damage in patients with diabetes mellitus]. Arkhiv oftalmologii Ukrainy. 2017; 5(3):18-22. Ukrainian https://doi.org/10.22141/2309-8147.5.3.2017.172339
Bezditko PA, Karliychuk MA, Lukhanin OO, Zavoloka OV. [Peculiarities of spectral coherence tomography using for investigation of the scleral lamina cribrosa thickness and the area of its scleral channel]. Kharkivska khirurgichna shkola. 2017; 3-4:63-9. Ukrainian
Amano S, Kaji Y, Oshika T, et al. Advanced glycation end products in human optic nerve head. Br J Ophthalmol. 2001 Jan; 85(1):52-5 https://doi.org/10.1136/bjo.85.1.52
Terai N, Spoerl E, Haustein M, et al. Diabetes mellitus affects biomechanical properties of the optic nerve head in the rat. Ophthalmic Res. 2012;47:189-94 https://doi.org/10.1159/000331990
Saylor M, McLoon LK, Harrison AR, et al. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009; 127(4):402-6 https://doi.org/10.1001/archophthalmol.2009.9
Simó R, Hernández C; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014; 25:23-33 https://doi.org/10.1016/j.tem.2013.09.005
Volchegorskiy IA, Moskvichiova MG, Chaschchina EN. [Effect of Mexidolum on manifestations of symmetric distal polyneuropathy in diabetic patients with diabetic foot syndrome]. Farmateka. 2007; 20:76-9. Russian
Gorshkov IP, Chernykh TM. [Treatment with ethyl methyl hydroxypyridine succinate combined with B-vitamin-like substances in type 2 diabetes patients with diabetic polyneuropathy]. Molodoi uchenyi. 2015;22:255-60. Russian
Grieb P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs. 2014 Mar;28(3):185-93 https://doi.org/10.1007/s40263-014-0144-8
Zerbini G, Bandello F, Lattanzio R, et al. In vivo Evaluation of Retinal and Choroidal Structure in a Mouse Model of Long-Lasting Diabetes. Effect of Topical Treatment with Citicoline. J Ocul Dis Ther. 2015;3(1):1-8 https://doi.org/10.12974/2309-6136.2015.03.01.1
Oshitari T, Yoshida-Hata N, Yamamoto S. Effect of neurotrophic factors on neuronal apoptosis and neurite regeneration in cultured rat retinas exposed to high glucose. Brain Res. 2010; 1346:43-51 https://doi.org/10.1016/j.brainres.2010.05.073
Liu Y, Li N, Ran XW. Clinical effect of ligustrazine combined with citicoline for treatment of diabetic peripheral neuropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Jul;28(7):606-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 М. А. Карлійчук
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
